The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation

Takashi Yamaoka¹, Young Hak Kim², Shigeaki Iwatsubo¹, Yoshihiro Nishimura³, Yasuhiro Funada¹

Affiliations

¹ Department of Respiratory Medicine, Takatsuki General Hospital, Takatsuki, Japan.
² Department of Respiratory Medicine, Takatsuki General Hospital, Takatsuki, Japan. Electronic address: ykim.free@gmail.com.
³ Department of Respiratory Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.

PMID: 34426001
DOI: 10.1016/j.jtho.2021.06.003

Free article

Comment

The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation

Takashi Yamaoka et al. J Thorac Oncol. 2021 Sep.

Free article

. 2021 Sep;16(9):e71-e72.

doi: 10.1016/j.jtho.2021.06.003.

Authors

Takashi Yamaoka¹, Young Hak Kim², Shigeaki Iwatsubo¹, Yoshihiro Nishimura³, Yasuhiro Funada¹

Affiliations

¹ Department of Respiratory Medicine, Takatsuki General Hospital, Takatsuki, Japan.
² Department of Respiratory Medicine, Takatsuki General Hospital, Takatsuki, Japan. Electronic address: ykim.free@gmail.com.
³ Department of Respiratory Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.

PMID: 34426001
DOI: 10.1016/j.jtho.2021.06.003

No abstract available

PubMed Disclaimer

Comment in

Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
Zhao H, Zhang Z, Zhang L. Zhao H, et al. J Thorac Oncol. 2021 Sep;16(9):e72-e76. doi: 10.1016/j.jtho.2021.07.013. J Thorac Oncol. 2021. PMID: 34426002 No abstract available.

Comment on

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Zhao H, et al. J Thorac Oncol. 2021 Sep;16(9):1533-1546. doi: 10.1016/j.jtho.2021.05.006. Epub 2021 May 24. J Thorac Oncol. 2021. PMID: 34033974 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation

Affiliations

The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous